91 related articles for article (PubMed ID: 16165104)
21. Does ketamine mimic aspects of schizophrenic speech?
Covington MA; Riedel WJ; Brown C; He C; Morris E; Weinstein S; Semple J; Brown J
J Psychopharmacol; 2007 May; 21(3):338-46. PubMed ID: 17591660
[TBL] [Abstract][Full Text] [Related]
22. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
23. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
24. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
Ehrenreich H; Hinze-Selch D; Stawicki S; Aust C; Knolle-Veentjer S; Wilms S; Heinz G; Erdag S; Jahn H; Degner D; Ritzen M; Mohr A; Wagner M; Schneider U; Bohn M; Huber M; Czernik A; Pollmächer T; Maier W; Sirén AL; Klosterkötter J; Falkai P; Rüther E; Aldenhoff JB; Krampe H
Mol Psychiatry; 2007 Feb; 12(2):206-20. PubMed ID: 17033631
[TBL] [Abstract][Full Text] [Related]
25. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
[TBL] [Abstract][Full Text] [Related]
26. [Ketamine and evoked potentials].
Kochs E; Bischoff P
Anaesthesist; 1994 Nov; 43 Suppl 2():S8-14. PubMed ID: 7840419
[TBL] [Abstract][Full Text] [Related]
27. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
28. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
[TBL] [Abstract][Full Text] [Related]
29. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
30. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
[TBL] [Abstract][Full Text] [Related]
31. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
32. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
33. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
34. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
[TBL] [Abstract][Full Text] [Related]
35. Relations among intelligence, executive function, and P300 event related potentials in schizophrenia.
Dichter GS; van der Stelt O; Boch JL; Belger A
J Nerv Ment Dis; 2006 Mar; 194(3):179-87. PubMed ID: 16534435
[TBL] [Abstract][Full Text] [Related]
36. Effects of quetiapine on cognitive functions in schizophrenic patients: a preliminary single-trial ERP analysis.
Zhang Y; Lehmann M; Shobeiry A; Höfer D; Johannes S; Emrich HM; Dietrich DE
Pharmacopsychiatry; 2009 Jul; 42(4):129-34. PubMed ID: 19585390
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
38. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
Fagerlund B; Søholm B; Fink-Jensen A; Lublin H; Glenthøj BY
Clin Neuropharmacol; 2007; 30(1):3-12. PubMed ID: 17272964
[TBL] [Abstract][Full Text] [Related]
39. Inherited auditory-cortical dysfunction in twin pairs discordant for schizophrenia.
Ahveninen J; Jääskeläinen IP; Osipova D; Huttunen MO; Ilmoniemi RJ; Kaprio J; Lönnqvist J; Manninen M; Pakarinen S; Therman S; Näätänen R; Cannon TD
Biol Psychiatry; 2006 Sep; 60(6):612-20. PubMed ID: 16876141
[TBL] [Abstract][Full Text] [Related]
40. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
